NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD.

Highlights Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Equities

603707

CNE100002WP3

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 10/05/2024 am IST			5-day change	1st Jan Change
13.9 ^CNY	+0.43%		+1.46%	-7.33%

01/05	NKFPharma Gets Nod to Register New Cancer Treatment	MT
27/04	Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NKFPharma Gets Nod to Register New Cancer Treatment	01/05	MT
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	27/04	CI
King-Friend Biochemical Pharmaceutical's Unit Gets US FDA Nod to Market Oxaliplatin Injection	16/01	MT
NKFPharma Gets Certificate to Register Voriconazole for Injection	11/01	MT
King-Friend Biochemical Pharma Gets Certificates for Registration of Micafungin Sodium for Injection	22/12	MT
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Announces an Exclusive Licensing Agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to Commercialize Three Insulin Biosimilars - Insulin Aspart, Insulin Lispro, and Insulin Glargine in the U.S	21/23/21	CI
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
NKFPharma Unit Gets US FDA's Nod for Plerixafor Injection	26/23/26	MT
NKFPharma Unit Gets FDA Greenlight to Market Anesthetic in the US	27/23/27	MT
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	28/23/28	CI
NKFPharma Gets Certification for Lung Cancer Drug	11/23/11	MT
NKFPharma's Nadroparin Calcium Injection Passes Drug Regulator’s Evaluation	21/23/21	MT
Nanjing King-friend Unit’s Anti-Cancer Drug Enters US Market	15/22/15	MT
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	28/22/28	CI
King-Friend Biochemical Wins FDA Nod to Market Cancer Treatment in US	08/22/08	MT
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	26/22/26	CI
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	29/21/29	CI
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	02/21/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Equities

603707

CNE100002WP3

Highlights

Filters